Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 435983, 13 pages
http://dx.doi.org/10.1155/2014/435983
Review Article

Genetic Abnormalities in Chronic Lymphocytic Leukemia: Where We Are and Where We Go

1Laboratori de Citogenètica Molecular, Servei de Patologia, Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona, Spain
2GRETNHE, Programa de Recerca en Càncer, Institut Hospital del Mar d’Investigacions Mèdiques, Doctor Aiguader 88, 08003 Barcelona, Spain
3Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Doctor Aiguader 88, 08003 Barcelona, Spain

Received 13 March 2014; Accepted 22 April 2014; Published 22 May 2014

Academic Editor: Ana Eugenia Rodríguez-Vicente

Copyright © 2014 Anna Puiggros et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Hallek, B. D. Cheson, D. Catovsky et al., “Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute—Working Group 1996 guidelines,” Blood, vol. 111, no. 12, pp. 5446–5456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Döhner, S. Stilgenbauer, A. Benner et al., “Genomic aberrations and survival in chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 343, no. 26, pp. 1910–1916, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. S. N. Malek, “The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia,” Oncogene, vol. 32, no. 23, pp. 2805–2817, 2013. View at Publisher · View at Google Scholar
  4. P. Baliakas, M. Iskas, A. Gardiner et al., “Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data,” The American Journal of Hematology, vol. 89, no. 3, pp. 249–255, 2014. View at Publisher · View at Google Scholar
  5. G. A. Calin, C. D. Dumitru, M. Shimizu et al., “Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15524–15529, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Klein, M. Lia, M. Crespo et al., “The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia,” Cancer Cell, vol. 17, no. 1, pp. 28–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Ouillette, H. Erba, L. Kujawski, M. Kaminski, K. Shedden, and S. N. Malek, “Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14,” Cancer Research, vol. 68, no. 4, pp. 1012–1021, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Mosca, S. Fabris, M. Lionetti et al., “Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion,” Clinical Cancer Research, vol. 16, no. 23, pp. 5641–5653, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Ouillette, R. Collins, S. Shakhan et al., “The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia,” Clinical Cancer Research, vol. 17, no. 21, pp. 6778–6790, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Parker, M. J. J. Rose-Zerilli, A. Parker et al., “13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia,” Leukemia, vol. 25, no. 3, pp. 489–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. C. S. Tam, T. D. Shanafelt, W. G. Wierda et al., “De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience,” Blood, vol. 114, no. 5, pp. 957–964, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. Hernández, A. E. Rodríguez, M. González et al., “A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia,” Haematologica, vol. 94, no. 3, pp. 364–371, 2009. View at Publisher · View at Google Scholar
  13. D. L. van Dyke, T. D. Shanafelt, T. G. Call et al., “A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 148, no. 4, pp. 544–550, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Dal Bo, F. M. Rossi, D. Rossi et al., “13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia,” Genes, Chromosomes and Cancer, vol. 50, no. 8, pp. 633–643, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Marasca, R. Maffei, S. Martinelli et al., “Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone,” Hematological Oncology, vol. 31, no. 2, pp. 348–355, 2013. View at Publisher · View at Google Scholar
  16. K. S. Reddy, “Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel,” The British Journal of Haematology, vol. 132, no. 6, pp. 705–722, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. G. W. Dewald, S. R. Brockman, S. F. Paternoster et al., “Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 121, no. 2, pp. 287–295, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Chena, J. S. Avalos, R. F. Bezares et al., “Biallelic deletion 13q14.3 in patients with chronic lymphocytic leukemia: cytogenetic, FISH and Clinical Studies,” The European Journal of Haematology, vol. 81, no. 2, pp. 94–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. E. M. Orlandi, P. Bernasconi, C. Pascutto et al., “Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH,” Hematological Oncology, vol. 31, no. 3, pp. 136–142, 2013. View at Publisher · View at Google Scholar
  20. R. Garg, W. Wierda, A. Ferrajoli et al., “The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia,” Cancer, vol. 118, no. 14, pp. 3531–3537, 2012. View at Publisher · View at Google Scholar
  21. A. Puiggros, J. Delgado, A. Rodriguez-Vicente et al., “Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion,” The British Journal of Haematology, vol. 163, no. 1, pp. 47–54, 2013. View at Publisher · View at Google Scholar
  22. D. Mertens, S. Wolf, C. Tschuch et al., “Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 20, pp. 7741–7746, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Sampath, C. Liu, K. Vasan et al., “Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia,” Blood, vol. 119, no. 5, pp. 1162–1172, 2012. View at Publisher · View at Google Scholar
  24. A. E. Rodríguez, J. Á. Hernández, R. Benito et al., “Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14,” PLoS ONE, vol. 7, no. 11, 2012. View at Publisher · View at Google Scholar
  25. S. Jeromin, S. Weissmann, C. Haferlach et al., “SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients,” Leukemia, vol. 28, no. 1, pp. 108–117, 2014. View at Publisher · View at Google Scholar
  26. D. Rossi, S. Rasi, V. Spina et al., “Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia,” Blood, vol. 121, no. 8, pp. 1403–1412, 2013. View at Publisher · View at Google Scholar
  27. D. Roos-Weil, F. Nguyen-Khac, S. Chevret et al., “Mutational and cytogenetic analyses Of 177 CLL patients with trisomy 12: a retrospective study of the CLL french intergroup,” Blood, vol. 122, no. 21, p. 4144, 2013. View at Google Scholar
  28. D. G. Oscier, J. Stevens, T. J. Hamblin, R. M. Pickering, R. Lambert, and M. Fitchett, “Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 76, no. 3, pp. 352–358, 1990. View at Google Scholar · View at Scopus
  29. E. Matutes, D. Oscier, J. Garcia-Marco et al., “Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients,” The British Journal of Haematology, vol. 92, no. 2, pp. 382–388, 1996. View at Publisher · View at Google Scholar
  30. R. Gunnarsson, L. Mansouri, A. Isaksson et al., “Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia,” Haematologica, vol. 96, no. 8, pp. 1161–1169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Quijano, A. López, A. Rasillo et al., “Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia,” Cytometry B: Clinical Cytometry, vol. 74, no. 3, pp. 139–149, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. V. Gattei, P. Bulian, M. I. del Principe et al., “Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia,” Blood, vol. 111, no. 2, pp. 865–873, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Balatti, A. Bottoni, A. Palamarchuk et al., “NOTCH1 mutations in CLL associated with trisomy 12,” Blood, vol. 119, no. 2, pp. 329–331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Landau, S. L. Carter, P. Stojanov et al., “Evolution and impact of subclonal mutations in chronic lymphocytic leukemia,” Cell, vol. 152, no. 4, pp. 714–726, 2013. View at Publisher · View at Google Scholar
  35. E. Falisi, E. Novella, C. Visco et al., “B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities,” Hematological Oncology, vol. 32, no. 1, pp. 22–30, 2014. View at Publisher · View at Google Scholar
  36. L. Sellmann, S. Gesk, C. Walter et al., “Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 138, no. 2, pp. 217–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. R. Ibbotson, A. Athanasiadou, L.-A. Sutton et al., “Coexistence of trisomies of chromosomes 12 and 19 in chronic lymphocytic leukemia occurs exclusively in the rare IgG-positive variant,” Leukemia, vol. 26, no. 1, pp. 170–172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Athanasiadou, K. Stamatopoulos, A. Tsompanakou et al., “Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis,” Cancer, Genetics and Cytogenetics, vol. 168, no. 2, pp. 109–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. C. López, J. Delgado, D. Costa et al., “Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations,” Genes, Chromosomes and Cancer, vol. 51, no. 9, pp. 881–889, 2012. View at Publisher · View at Google Scholar
  40. D. Winkler, C. Schneider, A. Kröber et al., “Protein expression analysis of chromosome 12 candidate genes in chronic lymphocytic leukemia (CLL),” Leukemia, vol. 19, no. 7, pp. 1211–1215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Haslinger, N. Schweifer, S. Stilgenbauer et al., “Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status,” Journal of Clinical Oncology, vol. 22, no. 19, pp. 3937–3949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  42. D. L. Kienle, C. Korz, B. Hosch et al., “Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes,” Journal of Clinical Oncology, vol. 23, no. 16, pp. 3780–3792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Porpaczy, M. Bilban, G. Heinze et al., “Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12,” The European Journal of Clinical Investigation, vol. 39, no. 7, pp. 568–575, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Koníková and J. Kusenda, “Altered expression of p53 and MDM2 proteins in hematological malignancies,” Neoplasma, vol. 50, no. 1, pp. 31–40, 2003. View at Google Scholar · View at Scopus
  45. T. Zenz, D. Mertens, R. Küppers, H. Döhner, and S. Stilgenbauer, “From pathogenesis to treatment of chronic lymphocytic leukaemia,” Nature Reviews Cancer, vol. 10, no. 1, pp. 37–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. R. Gunn, M. K. Hibbard, S. H. Ismail et al., “Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia,” Leukemia, vol. 23, no. 5, pp. 1011–1017, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. A. C. Gardiner, M. M. Corcoran, and D. G. Oscier, “Cytogenetic, fluorescence in situ hybridisation, and clinical evaluation of translocations with concomitant deletion at 13q14 in chronic lymphocytic leukaemia,” Genes, Chromosomes and Cancer, vol. 20, no. 1, pp. 73–81, 1997. View at Google Scholar
  48. P. Ouillette, R. Collins, S. Shakhan et al., “Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia,” Blood, vol. 118, no. 11, pp. 3051–3061, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Ouillette, J. Li, R. Shaknovich et al., “Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia,” Genes, Chromosomes and Cancer, vol. 51, no. 12, pp. 1125–1132, 2012. View at Publisher · View at Google Scholar
  50. D. Rossi, M. Fangazio, S. Rasi et al., “Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia,” Blood, vol. 119, no. 12, pp. 2854–2862, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. M. J. Rose-Zerilli, J. Forster, H. Parker et al., “ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial,” Haematologica, vol. 99, no. 4, pp. 736–742, 2014. View at Publisher · View at Google Scholar
  52. W. G. Wierda, S. O'Brien, X. Wang et al., “Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 29, no. 31, pp. 4088–4095, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A.-M. Tsimberidou, C. Tam, L. V. Abruzzo et al., “Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia,” Cancer, vol. 115, no. 2, pp. 373–380, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Delgado, B. Espinet, A. C. Oliveira et al., “Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results,” The British Journal of Haematology, vol. 157, no. 1, pp. 67–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Wawrzyniak, A. Kotkowska, J. Z. Blonski et al., “Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance,” The European Journal of Haematology, vol. 92, no. 2, pp. 91–101, 2014. View at Publisher · View at Google Scholar
  56. S. Stilgenbauer, T. Zenz, D. Winkler et al., “Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group,” Journal of Clinical Oncology, vol. 27, no. 24, pp. 3994–4001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Hallek, K. Fischer, G. Fingerle-Rowson et al., “Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial,” The Lancet, vol. 376, no. 9747, pp. 1164–1174, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Döhner, K. Fischer, M. Bentz et al., “p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias,” Blood, vol. 85, no. 6, pp. 1580–1589, 1995. View at Google Scholar · View at Scopus
  59. D. Oscier, R. Wade, Z. Davis et al., “Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation,” Haematologica, vol. 95, no. 10, pp. 1705–1712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Catovsky, S. Richards, E. Matutes et al., “Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial,” The Lancet, vol. 370, no. 9583, pp. 230–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. D. Rossi, H. Khiabanian, V. Spina et al., “Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia,” Blood, vol. 123, no. 14, pp. 2139–2147, 2014. View at Publisher · View at Google Scholar
  62. T. Zenz, A. Kröber, K. Scherer et al., “Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up,” Blood, vol. 112, no. 8, pp. 3322–3329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Zenz, D. Vollmer, M. Trbusek et al., “TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations,” Leukemia, vol. 24, no. 12, pp. 2072–2079, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Gonzalez, P. Martinez, R. Wade et al., “Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial,” Journal of Clinical Oncology, vol. 29, no. 16, pp. 2223–2229, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Asslaber, J. D. Piñón, I. Seyfried et al., “microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia,” Blood, vol. 115, no. 21, pp. 4191–4197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Z. Rassenti, S. Jain, M. J. Keating et al., “Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia,” Blood, vol. 112, no. 5, pp. 1923–1930, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Kröber, J. Bloehdorn, S. Hafner et al., “Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 24, no. 6, pp. 969–975, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. H. C. Rudenko, M. Else, C. Dearden et al., “Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation,” Leukemia & Lymphoma, vol. 49, no. 10, pp. 1879–1886, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Fabris, L. Mosca, K. Todoerti et al., “Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia,” Genes, Chromosomes and Cancer, vol. 47, no. 9, pp. 781–793, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. M. R. Grever, D. M. Lucas, G. W. Dewald et al., “Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997,” Journal of Clinical Oncology, vol. 25, no. 7, pp. 799–804, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. N. Jain and S. O'Brien, “Chronic lymphocytic leukemia with deletion 17p: emerging treatment options,” Oncology, vol. 26, no. 11, pp. 1067–1070, 2012. View at Google Scholar
  72. S. Cheng, J. Ma, A. Guo et al., “BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity,” Leukemia, vol. 28, no. 3, pp. 649–657, 2014. View at Publisher · View at Google Scholar
  73. J. A. Burger, “Bruton's Tyrosine Kinase (BTK) inhibitors in clinical trials,” Current Hematologic Malignancy Reports, vol. 9, no. 1, pp. 44–49, 2014. View at Publisher · View at Google Scholar
  74. A. J. Johnson, Y. Y. Yeh, L. L. Smith et al., “The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells,” Leukemia, vol. 26, no. 12, pp. 2554–2557, 2012. View at Publisher · View at Google Scholar
  75. M. S. Davis, A. Letai, and J. R. Brown, “Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition,” Leukemia & Lymphoma, vol. 54, no. 8, pp. 1823–1825, 2013. View at Publisher · View at Google Scholar
  76. G. Juliusson, D. G. Oscier, M. Fitchett et al., “Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities,” The New England Journal of Medicine, vol. 323, no. 11, pp. 720–724, 1990. View at Google Scholar · View at Scopus
  77. F. Dicker, S. Schnittger, T. Haferlach, W. Kern, and C. Schoch, “Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression,” Blood, vol. 108, no. 9, pp. 3152–3160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. C. Haferlach, F. Dicker, S. Schnittger, W. Kern, and T. Haferlach, “Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping,” Leukemia, vol. 21, no. 12, pp. 2442–2451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. N. A. Heerema, J. C. Byrd, P. S. Dal Cin et al., “Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study,” Cancer, Genetics and Cytogenetics, vol. 203, no. 2, pp. 134–140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Kotkowska, E. Wawrzyniak, J. Z. Blonski, T. Robak, and A. Korycka-Wolowiec, “Chromosomal aberrations in chronic lymphocytic leukemia detected by conventional cytogenetics with DSP30 as a single agent: comparison with FISH,” Leukemia Research, vol. 35, no. 8, pp. 1032–1038, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. G. M. Rigolin, F. Cibien, S. Martinelli et al., “Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with “normal” FISH: correlations with clinicobiologic parameters,” Blood, vol. 119, no. 10, pp. 2310–2313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. E. van den Neste, V. Robin, J. Francart et al., “Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine,” Leukemia, vol. 21, no. 8, pp. 1715–1722, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. S. M. Jaglowski, A. S. Ruppert, N. A. Heerema et al., “Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 159, no. 1, pp. 82–87, 2012. View at Publisher · View at Google Scholar
  84. A. Travella, L. Ripollés, A. Aventin et al., “Structural alterations in chronic lymphocytic leukaemia. Cytogenetic and FISH analysis,” Hematological Oncology, vol. 31, no. 2, pp. 339–347, 2013. View at Publisher · View at Google Scholar
  85. J. A. Woyach, G. Lozanski, A. S. Ruppert et al., “Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features,” Leukemia, vol. 26, no. 6, pp. 1442–1444, 2012. View at Publisher · View at Google Scholar
  86. C. Mayr, M. R. Speicher, D. M. Kofler et al., “Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia,” Blood, vol. 107, no. 2, pp. 742–751, 2006. View at Publisher · View at Google Scholar
  87. F. Cavazzini, J. A. Hernandez, A. Gozzetti et al., “Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis,” The British Journal of Haematology, vol. 142, no. 4, pp. 529–537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. N. Put, P. Meeus, B. Chatelain et al., “Translocation t(14;18) is not associated with inferior outcome in chronic lymphocytic leukemia,” Leukemia, vol. 23, no. 6, pp. 1201–1204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Put, K. van Roosbroeck, P. Konings et al., “Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course,” Annals of Hematology, vol. 91, no. 6, pp. 863–873, 2012. View at Publisher · View at Google Scholar
  90. Y. O. Huh, K. I.-C. Lin, F. Vega et al., “MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis,” The British Journal of Haematology, vol. 142, no. 1, pp. 36–44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Hruba, P. Dvorak, L. Weberova, and I. Subrt, “Independent coexistence of clones with 13q14 deletion at reciprocal translocation breakpoint and 13q14 interstitial deletion in chronic lymphocytic leukemia,” Leukemia & Lymphoma, vol. 53, no. 10, pp. 2054–2062, 2012. View at Publisher · View at Google Scholar
  92. S. Struski, C. Helias, C. Gervais et al., “13q deletions in B-cell lymphoproliferative disorders: frequent association with translocation,” Cancer, Genetics and Cytogenetics, vol. 174, no. 2, pp. 151–160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. C. López, T. Baumann, D. Costa et al., “A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 156, no. 5, pp. 612–618, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. J. A. Woyach, N. A. Heerema, J. Zhao et al., “Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease,” The British Journal of Haematology, vol. 148, no. 5, pp. 754–759, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. P. Ouillette, S. Fossum, B. Parkin et al., “Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks,” Clinical Cancer Research, vol. 16, no. 3, pp. 835–847, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. S. R. Gunn, M. S. Mohammed, M. E. Gorre et al., “Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia,” The Journal of Molecular Diagnostics, vol. 10, no. 5, pp. 442–451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. D. P. O'Malley, C. Giudice, A. S. Chang et al., “Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia,” International Journal of Laboratory Hematology, vol. 33, no. 3, pp. 238–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. R. Gunnarsson, A. Isaksson, M. Mansouri et al., “Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients,” Leukemia, vol. 24, no. 1, pp. 211–215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Puiggros, E. Puigdecanet, M. Salido et al., “Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescence in situ hybridization techniques?” Leukemia & Lymphoma, vol. 54, no. 5, pp. 986–995, 2013. View at Publisher · View at Google Scholar
  100. C. Schwaenen, M. Nessling, S. Wessendorf et al., “Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 4, pp. 1039–1044, 2004. View at Publisher · View at Google Scholar · View at Scopus
  101. L. Kujawski, P. Ouillette, H. Erba et al., “Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia,” Blood, vol. 112, no. 5, pp. 1993–2003, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Edelmann, K. Holzmann, F. Miller et al., “High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations,” Blood, vol. 120, no. 24, pp. 4783–4794, 2012. View at Publisher · View at Google Scholar
  103. N. E. Kay, J. E. Eckel-Passow, E. Braggio et al., “Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy,” Cancer, Genetics and Cytogenetics, vol. 203, no. 2, pp. 161–168, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Stilgenbauer, L. Bullinger, A. Banner et al., “Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia,” Leukemia, vol. 13, no. 9, pp. 1331–1334, 1999. View at Google Scholar · View at Scopus
  105. A. Cuneo, G. M. Rigolin, R. Bigoni et al., “Chronic lymphocytic leukemia with 6q—shows distinct hematological features and intermediate prognosis,” Leukemia, vol. 18, no. 3, pp. 476–483, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. E. Chapiro, N. Leporrier, I. Radford-Weiss et al., “Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages,” Leukemia Research, vol. 34, no. 1, pp. 63–68, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. A. Rinaldi, M. Mian, I. Kwee et al., “Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia,” The British Journal of Haematology, vol. 154, no. 5, pp. 590–599, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. F. Forconi, A. Rinaldi, I. Kwee et al., “Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion,” The British Journal of Haematology, vol. 143, no. 4, pp. 532–536, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. A. E. Rodríguez, C. Robledo, J. L. García et al., “Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling,” Annals of Oncology, vol. 23, no. 8, pp. 2138–2146, 2012. View at Publisher · View at Google Scholar
  110. S. R. Gunn, A. R. Bolla, L. L. Barron et al., “Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene,” Leukemia Research, vol. 33, no. 9, pp. 1276–1281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. P. J. Stephens, C. D. Greenman, B. Fu et al., “Massive genomic rearrangement acquired in a single catastrophic event during cancer development,” Cell, vol. 144, no. 1, pp. 27–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Cuneo, R. Bigoni, G. M. Rigolin et al., “Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance,” Haematologica, vol. 87, no. 1, pp. 44–51, 2002. View at Google Scholar · View at Scopus
  113. A. Schuh, J. Becq, S. Humphray et al., “Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns,” Blood, vol. 120, no. 20, pp. 4191–4196, 2012. View at Publisher · View at Google Scholar
  114. A. Janssens, N. van Roy, B. Poppe et al., “High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature,” The European Journal of Haematology, vol. 89, no. 1, pp. 72–80, 2012. View at Publisher · View at Google Scholar
  115. S. Stilgenbauer, S. Sander, L. Bullinger et al., “Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival,” Haematologica, vol. 92, no. 9, pp. 1242–1245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. A. Berkova, Z. Zemanova, M. Trneny et al., “Clonal evolution in chronic lymphocytic leukemia studied by interphase fluorescence in-situ hybridization,” Neoplasma, vol. 56, no. 5, pp. 455–458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  117. V. Quesada, L. Conde, N. Villamor et al., “Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia,” Nature Genetics, vol. 44, no. 1, pp. 47–52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. X. S. Puente, M. Pinyol, V. Quesada et al., “Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia,” Nature, vol. 475, no. 7354, pp. 101–105, 2011. View at Publisher · View at Google Scholar · View at Scopus